GLMD
Galmed Pharmaceuticals Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$4.63
+21.05%Latest reported
- Last report date
- Sep 2, 2026
- EPS actual
- -$2.86
- EPS estimate
- -$3.12
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -34.5%
- Revenue beats (12Q)
- 0
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Sep 2, 2026 | -$3.12 | -$2.86 | Beat 8.33% | — |
| May 20, 2026 | -$0.38 | -$0.92 | Miss -142.11% | — |
| Mar 31, 2026 | -$0.51 | -$0.73 | Miss -43.14% | — |
| Nov 26, 2025 | -$0.54 | -$0.33 | Beat 38.89% | — |
| Aug 28, 2025 | -$0.83 | $0.63 | Beat 175.90% | — |
| May 22, 2025 | -$0.89 | -$0.62 | Beat 30.34% | $1.5M |
| Nov 14, 2024 | — | -$2.31 | — | — |
| Aug 28, 2024 | — | $2.16 | — | — |
| May 30, 2024 | — | -$2.76 | — | — |
| Nov 22, 2023 | -$0.27 | -$2.88 | Miss -966.67% | — |
| Jun 1, 2023 | -$1.50 | -$13 | Miss -772.67% | — |
| Nov 16, 2022 | -$27 | -$38 | Miss -40.00% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Sep 2, 2026